BioCentury
ARTICLE | Company News

Tetra grants Shionogi Asian rights to Alzheimer's/fragile X candidate

January 4, 2019 1:03 AM UTC

Shionogi & Co. Ltd. (Tokyo:4507) received from Tetra Discovery Partners LLC (Grand Rapids, Mich.) exclusive rights in Japan, Korea and Taiwan to develop BPN14770 to treat brain disorders associated with dementia, including Alzheimer's disease and fragile X syndrome.

Tetra received a $35 million equity investment and a $5 million upfront payment from Shionogi. Tetra is eligible for up to $120 million in development and commercial milestones, plus royalties...